Biologic therapies in dermatology
- 1 January 2013
- journal article
- research article
- Published by Mark Allen Group in British Journal of Hospital Medicine
- Vol. 74 (1) , 12-17
- https://doi.org/10.12968/hmed.2013.74.1.12
Abstract
Biologic therapies, the anti-cytokines in particular, have proved to be a significant addition to the dermatologist’s armamentarium for the management of severe skin disease. This article summarizes the mechanism of action, dosage, approved indications, off-label uses and the future of biologic therapies in dermatology.Keywords
This publication has 27 references indexed in Scilit:
- Investigational VEGF antagonists for psoriasisExpert Opinion on Investigational Drugs, 2011
- Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With UstekinumabArchives of Dermatology, 2011
- Lack of effect of ustekinumab in treatment of allergic contact dermatitisContact Dermatitis, 2011
- Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 PatientsPublished by Elsevier ,2010
- A Pilot Study of Etanercept Treatment for Pemphigus VulgarisArchives of Dermatology, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)Journal of the American Academy of Dermatology, 2007
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trialGut, 2006
- Rook's Textbook of DermatologyPublished by Wiley ,2004